It has been a bruising few months for high-quality technology stocks, and even some of the ASX's most admired names have not been spared.
Pro Medicus Ltd (ASX: PME) shares are trading around $179.38, almost 50% below their all-time high of $336.
That decline has little to do with a deterioration in the company's underlying business. Instead, it reflects a broad sell-off in premium tech stocks, driven by concerns around AI valuations, disruption risks, and a general de-rating of high-multiple growth stocks.
Is this one of those rare opportunities to buy a world-class ASX share at a much more reasonable price than the market has offered for years?
Why Pro Medicus shares sold off
Pro Medicus has long traded on demanding valuation multiples, largely because it has delivered extraordinary growth with very high margins and a no balance sheet risk. In periods when markets become nervous about technology valuations, stocks like this are often sold first.
Recent concerns around an AI bubble have also weighed on valuations. Some investors appear to be reassessing how sustainable premium software valuations are across the sector.
Importantly, this pullback has not been triggered by weak results, lost contracts, or strategic missteps. It has been a valuation-led sell-off rather than a business-led one.
The business continues to perform
Pro Medicus' FY25 result highlighted just how strong the underlying momentum remains. Revenue rose 31.9% to $213 million, while net profit climbed 39.2% to $115.2 million. Cash and other financial assets increased to $210.7 million, and the company remains completely debt-free.
It was also a record year for contract wins, renewals, and expansions. During FY25 alone, Pro Medicus announced $520 million in new contracts and a further $130 million in renewals, alongside multiple upgrades from existing clients such as NYU Langone and Duke Health.
Management has been clear that the bulk of these contracts were signed in the second half of the year and are only now beginning to flow through to revenue. That creates a sizeable and visible earnings runway in FY26 and beyond.
Still early in a very large market
One of the most underappreciated aspects of the Pro Medicus story is how much growth opportunity remains. Despite its success, management estimates the company currently holds only around 10% of its total addressable market in the United States.
That alone suggests a long growth runway within radiology. Beyond that, Pro Medicus continues to expand into other ologies, including cardiology and digital pathology. The recent UCHealth contract, which includes the Visage 7 Cardiology offering, is a good example of how the platform is extending beyond its original core use case.
The shift toward fully cloud-based, full-stack deployments also strengthens the company's competitive position. Management has repeatedly pointed out that many competitors are still relying on hybrid systems, which can limit scalability and performance.
What the valuation is saying today
Even after the sell-off, Pro Medicus is not cheap by traditional metrics. Based on consensus estimates from CommSec, the company is expected to generate earnings per share of $1.50 in FY26, $1.95 in FY27, and $2.52 in FY28. At the current share price, that implies very high near-term PE ratios of 71 times to 119 times.
However, its valuation needs to be considered alongside growth quality and balance sheet strength. Pro Medicus is highly profitable, capital-light, and continues to sign long-duration contracts with some of the largest healthcare systems in the world. If consensus growth expectations are met, today's valuation looks far more reasonable on a forward-looking basis than it did at the peak.
A rare reset for a premium ASX name
Pro Medicus shares may remain volatile in the short term, particularly if global tech sentiment stays fragile. But stepping back, the investment case looks largely intact. The company continues to grow strongly, its addressable market remains vast, and its competitive advantages appear undiminished.
For investors who have long admired Pro Medicus but struggled to justify buying at extreme valuations, this pullback could prove to be one of the more attractive entry points the market has offered in a decade. It may not be risk-free, but opportunities to buy this calibre of ASX business at a materially lower price do not come around often.
